Soquelitinib Clinical Trials
3 recruitingDrug
Phase 22Phase 31
Showing 1–3 of 3 trials
Recruiting
Phase 2
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
Autoimmune Lymphoproliferative Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)15 enrolled3 locationsNCT06730126
Recruiting
Phase 3
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled34 locationsNCT06561048
Recruiting
Phase 2
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Atopic Dermatitis
Corvus Pharmaceuticals, Inc.200 enrolled1 locationNCT07441395